Preventive Treatment for Immunocompromised Individuals
Portions of the copy and language below are from the CDC.
Desert Oasis Healthcare is committed to improving our communities’ access to COVID-19 prevention and therapeutics. In addition to providing COVID-19 vaccines, DOHC can now provide the new pre-exposure prophylaxis treatment Pemgarda™ (pemivibart) to immunocompromised members. Pemgarda™ is a monoclonal antibody for people who are immunocompromised and unlikely to mount an adequate immune response to COVID-19 vaccination and who meet the FDA-authorized conditions for use.
Pemgarda™ is not a substitute for COVID-19 vaccination and is not authorized for treatment of COVID-19 or for post-exposure prophylaxis. Immunocompromised individuals should receive COVID-19 vaccination according to the recommended schedule. Per the pemivibart EUA, administration of pemivibart should be deferred for at least 2 weeks after a dose of COVID-19 vaccine.
Pemgarda™ at Desert Oasis Healthcare
Members should have a conversation with their primary care provider (PCP) and if deemed appropriate, a referral for infusion is required.
